Tag: aldehydes

April 27, 2017

Aldeyra Gets First Patient Enrolled in Phase 3 Trial

Aldeyra Therapeutics enrolled the first patient in their Phase 3 clinical trial of ADX-102.
April 20, 2017

Aldeyra Gets Orphan Drug Designation for ADX-102

Aldeyra Therapeutics received an orphan drug designation by the US Food and Drug Administration for ADX-102 in treating rare disease...
April 18, 2017

Aldeyra Doses Last Patient in Allergic Conjunctivitis Trial

Aldeyra Therapeutics announced the last patient dosing for its Phase 2b clinical trial of ADX-102 in allergic conjunctivitis.
February 14, 2017

Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...
January 25, 2017

Aldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs

LAldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...
November 14, 2016

Aldeyra Therapeutics Announces Third Quarter 2016 Financial Results

Aldeyra Therapeutics, a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported third...
September 15, 2016

Aldeyra Therapeutics Appoints Richard H. Douglas to Board of Directors

Aldeyra Therapeutics announced today that Richard H. Douglas will join the company's Board of Directors. Aldeyra is a biotech company...